美國CytoGenix www.cytogenix.com
CytoGenix和Omnimmune簽定了一項(xiàng)研發(fā)合作協(xié)議，它們將把CytoGenix的細(xì)胞內(nèi)表達(dá)技術(shù)和Omnimmune的單克隆抗體結(jié)合起來，以促進(jìn)用于診斷、預(yù)后、控制和防治癌癥的基因制品的輸送和靶向性。
CytoGenix的技術(shù)可生產(chǎn)未修飾的單鏈DNA(ssDNA)，這些ssDNA用于與反義技術(shù)、三聯(lián)技術(shù)、DNA疫苗和aptamer相關(guān)的催化和治療應(yīng)用。而Omnimmune的技術(shù)將提高CytoGenix的載體對特定細(xì)胞系的靶向性，促進(jìn)細(xì)胞對載體的攝取，并在細(xì)胞內(nèi)復(fù)制多個(gè)特定ssDNA序列。
CytoGenix, Inc. is a biopharmaceutical company that develops and markets innovative compounds and services based on its proprietary gene regulating and DNA production technologies. CytoGenix has products in pre-clinical development including an antimicrobial compound, DNA vaccines and anti-herpes and anti-inflammatory topical creams. The Company has developed a cell free process for synthesizing DNA which it uses for its own products as well as marketing specific compounds to other companies. CytoGenix, Inc. currently has 11 granted patents (1 US, 1 China, 9 Europe) covering our basic ssDNA expression technology, with one additional allowance (India) pending. We have an additional 11 applications pending in various countries which are currently progressing through the normal prosecution process. The Company actively collaborates with numerous academic centers of excellence, government agencies and biotechnology industry partners. Cytogenix, Inc. is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.